Table 4 Outcome
Primary immunodeficiencies (n = 20) | Idiopathic and post infectious (n = 39) | Other etiologies (n = 39) | All (n = 98) | P value | |
|---|---|---|---|---|---|
Follow-up time (months) | 110 [87.2;140.5] | 122.5 [83;156.2] | 114 [79.5;155.5] | 114 [84.5;153] | 0.92 |
Number of visits (mean ± SD) | 9.4 ± 3.7 | 9.4 ± 6.5 | 10.5 ± 5.4 | 9.8 ± 5.5 | 0.44 |
Admission (days/y) | 0.45 [0.05;4.675] | 1.4 [0.7;4.2] | 1.6 [0.3;6] | 1.35 [0.3;5.125] | 0.4 |
Admission in ICU | 1 (5%) | 9 (23.1%) | 7 (17.9%) | 17 (17.4%) | 0.22 |
Cardiovascular events | 0 | 3 (7.7%) | 3 (7.7%) | 6 (6.1%) | 0.44 |
Hemoptysis | 4 (20%) | 14 (35.9%) | 13 (33.3%) | 31 (31.6%) | 0.44 |
Exacerbation rate (/y) | 0.8 [0.525;1.475] | 0.6 [0.25;1.4] | 0.8 [0.3;1.5] | 0.8 [0.3;1.4] | 0.51 |
Pneumoniae | 12 (60%) | 19 (52.8%) | 24 (61.5%) | 55 (56.1%) | 0.48 |
Chronic colonization | 5 (25%)* | 22 (56.4%)* | 17 (43.6%) | 44 (44.9%) | 0.022 |
Aspergillus | 2 (10%) | 7 (17.9%) | 9 (23.1%) | 18 (18.4%) | 0.47 |
Pseudomonas aeruginosa | 4 (20%)§ | 18 (46.2%)§ | 11 (28.2%) | 33 (33.7%) | 0.05 |
NMT infection | 1 (5%) | 7 (17.9%) | 6 (15.4%) | 14 (14.3%) | 0.39 |
Lung function | |||||
FEV1 variation (mL/y) | −19.82 [−48.6;−16.1] | −22.86 [−36.7;−4.1] | −28.44 [−49.2;−11.2] | −25.03 [−43.9;−8.2] | 0.437 |
FEV1 variation (%/y) | −1.345 [− 2.5;−0.48] | −1.08 [− 1.85;0.34] | −1.5 [− 2.47;−0.15] | −1.31 [− 2.35;−0.10] | 0.48 |
FEV1/VC variation (%/y) | −0.605 [− 1.44;0.46] | −0.3 [− 1.25;0.39] | −1.00 [− 1.75;−0.27] | −0.55 [− 1.47;0.24] | 0.09 |
RV/TLC variation (%/y) | 1.14 [0.15;2.5] | 0.85 [−0.51;2.6] | 1,19 [−0.44;36] | 1.1 [− 0.06;2.7] | 0.81 |
Bhalla score variation(%/y) | 0.98 [0;2.5] | 1 [0;2.86] | 0.96 [0.52;2.77] | 0.95 [0;2.74] | 0.7 |
Deceased | 2 (10%) | 5 (12.8%) | 4 (10.3%) | 11 (11.2%) | 0.95 |
Respiratory cause | 1 (50%) | 4 (80%) | 3 (75%) | 8 (72.7%) | 0.72 |